Maximilian J Hochmair1, Alessandro Morabito2, Desiree Hao3, Cheng-Ta Yang4, Ross A Soo5, James C-H Yang6, Rasim Gucalp7, Balazs Halmos7, Lara Wang8, Amanda Golembesky9, Angela Märten10, Tanja Cufer11. 1. Department of Respiratory & Critical Care Medicine, Ludwig Boltzmann Institute of COPD & Respiratory Epidemiology, Otto Wagner Hospital, Sanatoriumstrasse 2, 1140 Vienna, Austria. 2. Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G.Pascale'-IRCCS, 80131 Napoli, Italy. 3. Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada. 4. Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 5. Department of Haematology-Oncology, National University Hospital, Singapore. 6. Department of Oncology, National Taiwan University Hospital & National Taiwan University Cancer Center, Taipei, Taiwan. 7. Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA. 8. Clinical Trials, Boehringer Ingelheim Taiwan Limited, Taiwan. 9. Epidemiology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 10. Medical Affairs Oncology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 11. Medical Faculty, University Clinic Golnik, University of Ljubljana, Ljubliana, Slovenia.
Abstract
AIM: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. RESULTS: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. CONCLUSION: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. TRIAL REGISTRATION NUMBER: NCT03370770.
AIM: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. RESULTS: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. CONCLUSION: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. TRIAL REGISTRATION NUMBER: NCT03370770.
Authors: Lotte Westerink; Jelmer L J Nicolai; Carl Samuelsen; Hans J M Smit; Pieter E Postmus; Ingolf Griebsch; Maarten J Postma Journal: Eur J Health Econ Date: 2020-04-23
Authors: Antonio Passaro; Filippo de Marinis; Hai-Yan Tu; Konstantin K Laktionov; Jifeng Feng; Artem Poltoratskiy; Jun Zhao; Eng Huat Tan; Maya Gottfried; Victor Lee; Dariusz Kowalski; Cheng Ta Yang; B J Srinivasa; Laura Clementi; Tejaswini Jalikop; Dennis Chin Lun Huang; Agnieszka Cseh; Keunchil Park; Yi-Long Wu Journal: Front Oncol Date: 2021-07-09 Impact factor: 6.244